Migraine And Headache
For individuals with migraine frequency of 4 to 14 episodes per month, prophylactic medications and analgesics are required.
Allergan has reported positive results from the first of 2 Phase 3 trials for ubrogepant for the treatment of migraine.
The FDA has granted GammaCore 510(k) expanded clearance to treat migraine related pain.
Amgen announced that erenumab met its primary endpoint in reducing monthly migraine days.
Prior physical or sexual abuse of survivors increased the likelihood of migraine or tension-type headache.
The PSEQ successfully shows the debility in migraine surgery patients, and puts migraine pain to perspective.
Patients were randomly assigned to receive eptinezumab (300mg or 100mg) or placebo once every 12 weeks.
For patients with chronic migraine, onabotulinumtoxinA was shown to have a better outcome.
In a case report, a 21 year old female's migraine was successfully treated with therapy specifically aimed at the herpes simplex virus.
Researchers report that a behavioral weight loss program may be effective in reducing migraine headaches as social support from a group of people facing similar circumstances may help patients cope.
The judicious use of caffeine as adjuvant therapy to over-the-counter pain relievers can improve or relieve pain for patients with migraine or tension-type headaches.
Women with migraine should avoid high-risk products such as combined oral HCs consisting of >35μg ethinylestradiol.
The FDA has accepted a BLA for the migraine prevention treatment, galcanezumab.
Over 25% of patients who end up in the emergency department for migraine typically require revisits for headache within 6 months.
The review suggests that magnesium is a safe, tolerable, and cost-effective treatment for migraine.
A systematic review aimed to validate whether stroke risk is increased in women taking estrogen-containing contraceptives who have a history of migraine.
Cefaly Acute and Cefaly Dual were approved for treating migraines.
A study identified distinguishing clinical characteristics of headaches associated with nontraumatic subarachnoid hemorrhage.
Both erenumab and fremanezumab are currently under review by the FDA for the treatment of migraine.
Although pharmacotherapy remains the standard strategy for migraine management, there are many patients for whom nonpharmacological approaches are indicated.
Patients with Parkinson disease had reductions in the intensity, frequency and overall severity of their headaches and migraines.
Clinicians need to consider treatments for episodic migraine that may be contraindicated if a patient also has cardiovascular disease.
The rapid screening tool may help to inform treatment decisions for at-risk patients.
Frequency of migraine with or without aura may be correlated with symptoms of anxiety and depression.
The investigators believe that ketamine may still hold some benefits for treatment of acute headache in the emergency department.
The efficacy of oral versus intranasal delivery of sumatriptan on migraine-related nausea was evaluated in the COMPASS study.
Pediatric patients with NDPH experience more sleep disturbances than those with migraine or tension-type headaches.
Despite mounting evidence suggesting the contrary, the debate on the potential benefits of patent foramen ovale closure for migraine is still ongoing.
Over half of all individuals included in this study reported headache attacks occurring at specific time periods throughout the day.
In the emergency department, it was found that IV prochlorperazine plus diphenhydramine was better than IV hydromorphone for treating migraine pain.
Neurology Advisor Articles
- Updated Ischemic Stroke Guidelines: Expert Takeaways
- Alternative Genetic Risk Variant for Alzheimer Disease Identified
- Advance Directives for Dementia: Honoring Patient Wishes When You Don't Know What They Are
- Ethical Considerations in New Coma Research
- Poor Sleep Associated With Worse PTSD, Chronic Pain in Youth
- Comparing Reference Points for Deep Brain Stimulation Location in Parkinson Disease
- FDA Approves Clinical Decision Support Tool for Stroke
- US Will Produce Radioisotope for MRI, FDA Says
- Cognitive Decline in Men Linked to Low Serum Sodium
- Solanezumab Every 4 Weeks Does Not Significantly Affect Cognitive Decline in Alzheimer Disease